Ranirestat

Summary

Ranirestat (CHEMBL334830) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including diabetic neuropathy and polyneuropathy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 420.2 Da · C17H11BrFN3O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL334830
Name	Ranirestat
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	153948
Molecular formula	C17H11BrFN3O4
Molecular weight	420.2
InChIKey	QCVNMNYRNIMDKV-QGZVFWFLSA-N

SMILES: C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F

IUPAC name: (3R)-2’-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4’-pyrrolo[1,2-a]pyrazine]-1’,2,3’,5-tetrone

Also known as: AS-3201, Ranirestat, RANIRESTAT

Patent coverage: 131 distinct patent families (351 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 348 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Aldo-keto reductase family 1 member B1, Aldo-keto reductase family 1 member B1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P80276	7.82	IC50	15	nM	CHEMBL_ACT_1239301
AKR1B1	7.82	IC50	15	nM	CHEMBL_ACT_2047862

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetic neuropathy	3	MONDO:0006626	EFO:1000783
polyneuropathy	2	MONDO:0001824	EFO:0009562

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00101426	PHASE3	COMPLETED	Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
NCT00927914	PHASE2/PHASE3	COMPLETED	Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).